| Glenmark Pharmaceuticals Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 532296 |
NSE Symbol : GLENMARK |
P/E(TTM) : 22.97 |
|
ISIN Demat : INE935A01035 |
Div & Yield% : 0.16 |
EPS(TTM) : 67.15 |
|
Book Value(₹) : 848.58 |
Market Cap(₹Cr) : 43,523.29 |
Face Value(₹) : 1.00 |
| Particulars | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|
| INCOME : | |||||
| Sales Turnover | 7,891.12 | 8,220.66 | 8,141.58 | 7,567.93 | 6,712.63 |
| Excise Duty | - | - | - | - | - |
| Net Sales | 7,891.12 | 8,220.66 | 8,141.58 | 7,567.93 | 6,712.63 |
| Other Income | 6,238.36 | 985.94 | 1,044.96 | 470.13 | 625.34 |
| Stock Adjustments | 103.07 | 31.37 | 16.13 | -5.24 | -48.77 |
| Total Income | 14,232.55 | 9,237.97 | 9,202.67 | 8,032.82 | 7,289.20 |
| EXPENDITURE : | |||||
| Raw Materials | 3,313.19 | 3,427.07 | 3,474.66 | 2,944.53 | 2,617.22 |
| Power and Fuel Cost | 104.92 | 95.09 | 91.34 | 80.49 | 90.76 |
| Other Manufacturing Expenses | 375.32 | 304.66 | 297.44 | 267.26 | 230.03 |
| Selling and Administration Expenses | 1,199.17 | 1,246.10 | 1,062.89 | 914.37 | 977.77 |
| Miscellaneous Expenses | 325.15 | 855.71 | 349.97 | 358.30 | 371.53 |
| Employee Benefit Expenses | 1,434.78 | 1,346.51 | 1,193.20 | 1,107.40 | 1,072.33 |
| Less: Preoperative Expenditure | - | - | - | - | - |
| Total Expenses | - | - | - | - | - |
| Operating Profit | 7,480.02 | 1,962.84 | 2,733.18 | 2,360.47 | 1,929.57 |
| Interest | 277.11 | 206.82 | 236.04 | 265.90 | 256.39 |
| Gross Profit | 7,202.91 | 1,756.02 | 2,497.14 | 2,094.57 | 1,673.18 |
| Depreciation | 202.16 | 184.15 | 159.70 | 150.82 | 138.54 |
| Profit Before Tax | 7,000.75 | 1,571.87 | 2,337.44 | 1,943.75 | 1,534.64 |
| Current Tax | 1,049.99 | 386.93 | 411.08 | 343.62 | 269.24 |
| Fringe Benefit tax | - | - | - | - | - |
| Deferred Tax | 783.46 | -23.83 | -71.42 | -49.31 | -89.14 |
| Reported Net Profit | 5,167.29 | 1,208.77 | 1,997.79 | 1,649.45 | 1,354.55 |
| Extraordinary Items | 3,742.26 | -369.56 | 354.02 | 59.87 | 14.43 |
| Adjusted Net Profit | 1,425.03 | 1,578.33 | 1,643.77 | 1,589.58 | 1,340.12 |
| Adjustment below Net Profit | -4.76 | 0.63 | 1.61 | 2.48 | -5.42 |
| Profit/Loss Balance carried down | 16,002.82 | 14,863.96 | 12,921.86 | 11,340.47 | 10,059.38 |
| Statutory Appropriations | - | - | - | - | - |
| Appropriations | 77.22 | 70.54 | 57.30 | 70.54 | 68.03 |
| P & L Balance carried down | 21,088.13 | 16,002.82 | 14,863.96 | 12,921.86 | 11,340.47 |
| Dividend | - | - | - | - | - |
| Preference Dividend | - | - | - | - | - |
| Equity Dividend (%) | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 |
| Dividend Per Share(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Earnings Per Share-Unit Curr | 183.11 | 42.84 | 70.80 | 58.46 | 48.00 |
| Earnings Per Share(Adj)-Unit Curr | 183.11 | 42.84 | 70.80 | 58.46 | 48.00 |
| Book Value | 814.01 | 633.57 | 593.21 | 524.84 | 468.73 |
| Book Value(Adj)-Unit Curr | 814.01 | 633.57 | 593.21 | 524.84 | 468.73 |